{"news": [{"date": "20240319060000", "headline": "Canadian First - Abbott Advances Chronic Pain Management with the World's Smallest Implanted, Rechargeable Spinal Cord Stimulation System", "summary": "Abbott (NYSE: ABT) today announced that the company's Eterna\u2122 SCS system \u2013 the smallest implantable, rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain,*3,4 has been used for the first time in Canada. The inaugural use case of the Eterna SCS system took place at H\u00f4pital de l'Enfant-J\u00e9sus hospital in Quebec City, marking a significant milestone in the Canadian adoption of this technology by making it widely accessible for people suffering from chronic pain."}, {"date": "20240319073010", "headline": "Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?", "summary": "The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?"}, {"date": "20240319114000", "headline": "Here's Why Investors Should Retain Abbott (ABT) Stock Now", "summary": "Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre."}, {"date": "20240319160017", "headline": "Abbott (ABT) Exceeds Market Returns: Some Facts to Consider", "summary": "In the most recent trading session, Abbott (ABT) closed at $113.16, indicating a +0.64% shift from the previous trading day."}, {"date": "20240320000100", "headline": "The Art of Valuation: Discovering Abbott Laboratories's Intrinsic Value", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240320155020", "headline": "Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade", "summary": "Abbott (ABT) closed at $111.50 in the latest trading session, marking a -1.47% move from the prior day."}, {"date": "20240321010000", "headline": "Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now", "summary": ""}, {"date": "20240321082503", "headline": "11 Best Healthcare ETFs To Buy Now", "summary": "In this article, we discuss 11 best healthcare ETFs to buy now. If you want to skip our discussion on the healthcare industry, head over to 5 Best Healthcare ETFs To Buy Now. In 2023, the healthcare sector faced challenges as investors adjusted portfolios in anticipation of higher interest rates. Although the sector lagged behind [\u2026]"}, {"date": "20240321122202", "headline": "3 Resilient Stocks to Protect Your Wealth During a Recession", "summary": "As the world economy teeters on the verge of instability, three titans have survived many financial storms and emerged stronger than ever from the waves of uncertainty. Here, recognizing these business titans\u2019 strategic acumen reveals a means to protect riches. Every firm has a different story of perseverance, but all are united by a persistent dedication to maximizing shareholder value in the face of hardship. With its strategy focusing on sales growth, margin expansion and operational efficien"}, {"date": "20240321152633", "headline": "3 Stocks to Buy Right Now for the Coming Recession", "summary": "Inflation came in much hotter than expected in February. Core services inflation, which excludes housing, rose 0.5% from January following a 0.9% increase from December. Last month\u2019s gain was twice as fast as it was pre-pandemic, causing the Federal Reserve to rethink interest cutting rate too soon. Consumer spending is weakening as real disposable income fell in January. At the same time, household debt hit an unsustainable $17.5 trillion. Credit card and auto loan debt is also at record levels"}, {"date": "20240321214200", "headline": "Abbott Laboratories stock underperforms Friday when compared to competitors", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240321223317", "headline": "15 Highest Paying Countries for Biomedical Engineers", "summary": "In this article, we will look at the 15 highest paying countries for biomedical engineers. We have also discussed the global bioengineering technology market. If you want to skip our detailed analysis, head straight to the 5 Highest Paying Countries for Biomedical Engineers. The global Bioengineering Technology Market exhibited remarkable growth, with a value of [\u2026]"}, {"date": "20240322022500", "headline": "Want Decades of Passive Income? 2 Stocks to Buy Now.", "summary": "There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing."}, {"date": "20240324073625", "headline": "14 Best Medical Device Stocks To Buy Now", "summary": "In this article, we will discuss the 14 Best Medical Device Stocks To Buy Now. You can skip our detailed analysis of the Medical Device Industry and go directly to the 5 Best Medical Device Stocks To Buy Now. The healthcare sector relies heavily on advancements in medical technology, which encompasses medical devices aiding in [\u2026]"}, {"date": "20240324084247", "headline": "16 Most Undervalued Large Cap Stocks To Buy According To Analysts", "summary": "In this article, we will be taking a look at the 16 most undervalued large-cap stocks to buy according to analysts. To skip our detailed analysis of current stock market dynamics, you can go directly to see the 5 Most Undervalued Large-Cap Stocks To Buy According To Analysts. The Fed\u2019s March Decision On March 20, [\u2026]"}, {"date": "20240324190600", "headline": "More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a \u2018Buy\u2019", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240324201600", "headline": "Abbott Laboratories (ABT) Shares Cross 2% Yield Mark", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240324214100", "headline": "Abbott Laboratories stock underperforms Monday when compared to competitors", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240325033602", "headline": "Abbott Laboratories : Receives CE Mark for its Groundbreaking Assert-IQ\u2122 Insertable Cardiac Monitor, Expanding Availability of Long-Term Monitoring for Irregular Heart Rhythms", "summary": "Assert-IQ offers the world's longest battery life\u2021 for a Bluetooth\u00ae enabled ICM A new addition to Abbott's portfolio of connected health devices, the Assert-IQ..."}, {"date": "20240325071500", "headline": "Abbott (ABT) Expands in Canada With First Eterna SCS Use", "summary": "Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology."}, {"date": "20240325105823", "headline": "30 Countries with Highest Proportion of Older Adults", "summary": "In this article, we will be covering the 30 countries with the highest proportion of older adults. If you wish to skip our detailed analysis, you can move directly to the 5 Countries with Highest Proportion of Older Adults. An Uptick in Population Ageing Currently, we are witnessing a trend of global population ageing as [\u2026]"}, {"date": "20240325214800", "headline": "Abbott Labs (ABT) Gets a Buy from Wells Fargo", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240325233400", "headline": "Court rules DexCom infringed one of three Abbott patents, Bloomberg Law reports", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240326040703", "headline": "25 Countries with Lowest Rates of Infant Mortality", "summary": "In this article, we will be taking a look at the 25 countries with lowest rates of infant mortality. If you do not want to learn about the global disparities in infant mortality, head straight to the 5 Countries with Lowest Rates of Infant Mortality. Infant mortality rates serve as a critical indicator of a [\u2026]"}, {"date": "20240326041837", "headline": "25 Countries with the Highest Death Rate From Malnutrition", "summary": "In this article, we will be taking a look at the 25 countries with the highest death rate from malnutrition. If you do not want to learn about the global malnutrition, head straight to the 5 Countries with the Highest Death Rate From Malnutrition. Countries with the highest death rate from malnutrition face a dire humanitarian [\u2026]"}, {"date": "20240326054500", "headline": "Winning Over Wall Street: 3 Stocks Earning Overwhelming Analyst Approval", "summary": "Seasoned investors typically pay close attention to \u201cstocks with analyst approval,\u201d a sign of potential success and resilience in the ever-volatile equity market landscape. Currently, we are in a period of rapid technological advancements in artificial intelligence (AI) and shifting economic paradigms amid expected interest rate cuts. Thus, the importance of relying on expert equity analysis has become even more pronounced on Wall Street. Stocks have been on a tear so far in 2024, with both the"}, {"date": "20240326070009", "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects."}, {"date": "20240326072152", "headline": "Reckitt Benckiser: Maybe Caution Is Appropriate", "summary": "Reckitt Benckiser reported mediocre full-year results for fiscal 2023 as well as a mediocre guidance for fiscal 2024. Explore more details here."}, {"date": "20240326160018", "headline": "Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know", "summary": "In the closing of the recent trading day, Abbott (ABT) stood at $111.50, denoting a +1.35% change from the preceding trading day."}, {"date": "20240327102500", "headline": "Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark", "summary": "Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow."}, {"date": "20240327143000", "headline": "Abbott Hosts Conference Call for First-Quarter Earnings", "summary": "Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens."}, {"date": "20240327200000", "headline": "Catalyst Watch: Tesla deliveries, Disney board vote, DJT drama and Fortinet event", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328034400", "headline": "May 10th Options Now Available For Abbott Laboratories (ABT)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240329085129", "headline": "3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List", "summary": "As the number of grey-haired people rises worldwide, investors need to notice the strong-buy healthcare stocks. The need for healthcare will grow as the number of people aged 60 years and older doubles by 2050, a situation never before witnessed in the world, thanks to smaller families and longer lifespans. All of this is great for strong buy healthcare stocks as they can target a huge addressable market. U.S. healthcare spending is estimated to reach a total market value of about $6.2 trillion"}, {"date": "20240401010000", "headline": "3 'Great Repeatable Business Models' (Dividend Aristocrats)", "summary": "As my readers and followers know, I'm always on the hunt for high quality income stocks. Check out these 3 undervalued dividend aristocrats."}, {"date": "20240401020300", "headline": "Abbott announces FDA clearance of i-STAT TBI cartridge", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401025700", "headline": "Abbott gets FDA clearance for i-STAT TBI cartridge for concussions", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401033519", "headline": "Abbott Laboratories Cartridge Gets FDA Clearance to be Used with Whole Blood", "summary": "By Denny Jacob Abbott Laboratories' i-STAT TBI cartridge received clearance from the Food and Drug Administration to be used with whole blood, offering an additional tool for people with..."}, {"date": "20240401070000", "headline": "Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside", "summary": "Abbott's i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests to help with the assessment of TBI were only cleared for use with plasma or serum, requiring samples to be sent to a lab for processing and testing."}, {"date": "20240401160020", "headline": "Abbott (ABT) Declines More Than Market: Some Information for Investors", "summary": "Abbott (ABT) concluded the recent trading session at $112.09, signifying a -1.38% move from its prior day's close."}, {"date": "20240401191000", "headline": "Russell 2000 Index Best And Worst Performing Stocks Of 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402000600", "headline": "Buy Rating Affirmed for Abbott Labs Following TriClip\u2019s Favorable FDA Approval and Market Outlook", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402020200", "headline": "Abbott receives FDA approval for TriClip", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402030500", "headline": "Abbott wins FDA approval for heart valve repair device", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402033629", "headline": "US FDA approves Abbott's heart valve repair device", "summary": "Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries...."}, {"date": "20240402070000", "headline": "Abbott Receives FDA Approval for TriClip\u2122, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve", "summary": "Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip\u2122 transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefi"}, {"date": "20240402072307", "headline": "UPDATE 3-Abbott's heart valve repair device gains US FDA approval", "summary": "Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device for patients with a potentially fatal heart disease, just months after rival Edwards Lifesciences received the regulator's nod for its device.  The Abbott device, TriClip, aims to treat tricuspid regurgitation (TR), which occurs when the valve separating the right lower chamber of the heart from the right upper does not close properly, causing blood to flow backwards.  In February, Edwards Lifesciences gained approval for a device that replaces the tricuspid valve."}, {"date": "20240402073629", "headline": "Abbott's heart valve repair device gains US FDA approval", "summary": "(Reuters) -Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device for patients with a potentially fatal heart disease, just months after rival Edwards Lifesciences received the regulator's nod for its device.  The Abbott device, TriClip, aims to treat tricuspid regurgitation (TR), which occurs when the valve separating the right lower chamber of the heart from the right upper does not close properly, causing blood to flow backwards.  In February, Edwards Lifesciences gained approval for a device that replaces the tricuspid valve."}, {"date": "20240402091800", "headline": "Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval", "summary": "Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion."}, {"date": "20240402225100", "headline": "Abbott price target raised by $2 at Citi, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240403044944", "headline": "ABBOTT RECEIVES FDA APPROVAL FOR TRICLIP, FIRST-OF-ITS-KIND DEVICE TO REPAIR LEAKY TRICUSPID HEART VALVE", "summary": "ABBOTT PARK - Abbott today announced that the U.S. Food and Drug Administration has approved the company s first-of-its-kind TriClip transcatheter edge-to-edge repair system that s specifically..."}, {"date": "20240403210900", "headline": "Buy Rating Reaffirmed for Abbott Labs Amid Strong Growth and New Product Launches", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240405054711", "headline": "BME: Trading At A Historical Discount To NAV", "summary": "BlackRock Health Sciences Trust offers 6.35% dividend yield & discounted NAV, providing an opportunity to benefit from healthcare sector growth. Learn more on BME CEF here."}, {"date": "20240405073011", "headline": "Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?", "summary": "According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?"}, {"date": "20240405075200", "headline": "Abbott (ABT) Receives FDA's Approval for the TriClip TEER System", "summary": "Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve."}, {"date": "20240405145500", "headline": "Top Analyst Reports for T-Mobile US, Abbott Laboratories & Palo Alto Networks", "summary": "Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW)."}, {"date": "20240406030445", "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of April 7", "summary": "Get the latest updates on dividend activity for Dividend Champions, Contenders, and Challengers, including changes, ex-dividend dates, and pay dates."}, {"date": "20240408070011", "headline": "Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know", "summary": "Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects."}, {"date": "20240408071300", "headline": "The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services", "summary": "T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services are part of the Zacks top Analyst Blog."}, {"date": "20240408081000", "headline": "Abbott (ABT) Faces Low Testing Demand, Currency Headwinds", "summary": "Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering."}, {"date": "20240408115050", "headline": "Ten doctors on FDA panel reviewing Abbott heart device had financial ties with company", "summary": "The FDA didn\u2019t disclose that most of them had received payments from the company or conducted research it had funded."}, {"date": "20240409021700", "headline": "Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409155018", "headline": "Abbott (ABT) Rises Higher Than Market: Key Facts", "summary": "The latest trading day saw Abbott (ABT) settling at $112.44, representing a +1.74% change from its previous close."}, {"date": "20240410112218", "headline": "7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape", "summary": "With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and services. It\u2019s one of the essentials of life, which makes the industry such a politically sensitive matter. Besides the critical need, another element that helps bolster the case for healthcare stocks is the underlying diversity. Yes, the sector centers on the pharmaceutical innovation space. However,"}, {"date": "20240410193500", "headline": "Abbott Laboratories Unusual Options Activity", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411030257", "headline": "DexCom Is Pricey For A Reason - Its Growth Story Reflects That", "summary": "DexCom has demonstrated robust growth in revenue and operating income. Read more to see why I rate DXCM stock as a buy."}, {"date": "20240411034200", "headline": "Interesting ABT Put And Call Options For May 31st", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411041500", "headline": "Got $200? 2 Healthcare Stocks to Buy and Hold Forever.", "summary": "These companies provide stability, reliability, and passive income."}, {"date": "20240411050226", "headline": "Abbott Laboratories's Dividend Analysis", "summary": "Abbott Laboratories (NYSE:ABT) recently announced a dividend of $0.55 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-12.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's look into Abbott Laboratories's dividend performance and assess its sustainability."}, {"date": "20240411073100", "headline": "Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable", "summary": "Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions."}, {"date": "20240411200000", "headline": "Catalyst Watch: Boeing hearing, Bitcoin halving event and new eyes on Reddit", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411201611", "headline": "Practical Lessons From NCS Multistage Inc v. Kobold Corporation", "summary": "The Federal Court decision in NCS Multistage Inc v. Kobold Corporation, released late last year, addressed six patents related to drilling multistage horizontal oil wells.1 NCS and Kobold are..."}, {"date": "20240411221400", "headline": "Abbott Laboratories Dividend Stock Analysis", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412014900", "headline": "Jim Cramer Calls Cummins 'Terrific,' Recommends Selling This Chinese Auto Manufacturer", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412060036", "headline": "Why Wall Street Got Even More Excited About The Glucose Monitor \u2014 And How Dexcom, Abbott Labs Stand To Benefit", "summary": "Metabolic health is all the rage, helped by the advent of weight-loss drugs and continuous glucose monitors. Can they change disease forever?"}, {"date": "20240412071523", "headline": "Ahead of Abbott (ABT) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics", "summary": "Evaluate the expected performance of Abbott (ABT) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight."}, {"date": "20240412075100", "headline": "What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?", "summary": "Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets."}, {"date": "20240412204400", "headline": "3 Buy Rated Stocks To Consider As Earnings Approach", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240413101824", "headline": "Jim Cramer\u2019s 10 Favorite Healthcare Stock Picks in 2024", "summary": "In this article, we will take a detailed look at Jim Cramer\u2019s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer\u2019s 5 Favorite Healthcare Stock Picks in 2024. Jim Cramer kicked off 2024 with a positive note for the healthcare sector, saying in a program in January that the [\u2026]"}, {"date": "20240413230100", "headline": "Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240414010600", "headline": "Earnings week ahead: BAC, JNJ, TSM, UNH, ABT, SLB, UAL, PG, NFLX and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240414015101", "headline": "Wall Street Breakfast: The Week Ahead", "summary": "Geopolitical tensions in the Middle East, earnings reports from major companies, and the upcoming bitcoin halving event are set to drive market focus this..."}, {"date": "20240415000100", "headline": "Options Volatility and Implied Earnings Moves This Week, April 15 \u2013 April 19, 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415001800", "headline": "Abbott Laboratories a Top 25 Dividend Giant With 2.02% Yield (ABT)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415034600", "headline": "Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415040400", "headline": "Abbott Laboratories (ABT)'s Winning Formula: Financial Metrics and Competitive Strengths", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415045700", "headline": "Netflix and United Airlines to report highest move post earnings: BofA", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415063000", "headline": "Abbott, Thoratec recall HeartMate ventricular systems due to obstruction issue", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415094258", "headline": "Abbott\u2019s latest Heartmate recall tied to 273 injuries, 14 deaths", "summary": "Biological material can build up and obstruct blood flow in heart failure patients supported by the left ventricular assist devices, the FDA said."}, {"date": "20240415143500", "headline": "Q1 '24 S&P 500 Earnings (And Johnson & Johnson): Expecting Another Normal Earnings Season", "summary": "The \u00e2\u0080\u009cexpected\u00e2\u0080\u009d Q1 \u00e2\u0080\u009924 S&P 500 EPS growth has fallen to +2.7% as of Friday, April 12th, \u00e2\u0080\u009924 (down from +5% as of last Friday, April 5th."}, {"date": "20240416040100", "headline": "Notable earnings before Wednesday's open", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416061300", "headline": "Abbott Q1 Earnings Preview: Return of core business strength could benefit top line", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416061300", "headline": "Notable companies reporting before tomorrow\u00e2\ufffd\ufffd\ufffd\ufffds open", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416102442", "headline": "FHLC: Healthcare Dashboard For April", "summary": "Fidelity MSCI\u00c2\u00a0Health Care\u00c2\u00a0Index ETF is an alternative to XLV for long-term investors. Read this article to learn more about FHLC ETF."}, {"date": "20240416191300", "headline": "Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416191300", "headline": "Investor Optimism Decreases; Dow Ends 6-Session Losing Streak", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416191400", "headline": "Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What's Driving Markets Wednesday?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416210000", "headline": "RBC Capital Remains a Buy on Abbott Labs (ABT)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416213300", "headline": "What You Missed On Wall Street On Wednesday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416221500", "headline": "Earnings Scheduled For April 17, 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416232551", "headline": "Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings", "summary": "Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. See why ABT stock is a Buy."}, {"date": "20240417000100", "headline": "Abbott Laboratories: An Exploration into Its Intrinsic Value", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417000600", "headline": "Options Volatility and Implied Earnings Moves Today, April 17, 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417001100", "headline": "Wall Street Poised To Rebound From Slump As Earnings Optimism Grows: Analyst Eyes This S&P 500 Level As Attractive Entry Point", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417002402", "headline": "Futures inch up on megacap support; earnings, Fed comments on tap", "summary": "U.S. stock index futures rose onWednesday as most megacap growth stocks gained, while investorsawaited earnings and commentary from the central bank'spolicymakers to gauge how corporate America was..."}, {"date": "20240417003100", "headline": "Abbott reports Q1 adjusted EPS 98c, consensus 95c", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417003300", "headline": "Abbott sees Q2 adjusted EPS $1.08-$1.12, consensus $1.12", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417003300", "headline": "Abbott revises FY24 adjusted EPS view to $4.55-$4.70 from $4.50-$4.70", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417003500", "headline": "Abbott Laboratories Non-GAAP EPS of $0.98 beats by $0.03, raises midpoint of FY guidance ranges", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417003500", "headline": "Abbott reports Q1 worldwide Medical Devices sales up 14.2% on reported basis", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417003600", "headline": "Abbott reports Q1 worldwide COVID-19 testing sales $204M vs. $730M last year", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417005200", "headline": "Abbott in charts: Q1 sees strong results in Medical Devices and Established Pharmaceuticals", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417010000", "headline": "Low Risk, High Return? The Power Of The 15-Stock Dividend Growth Portfolio", "summary": "Dividends have contributed significantly to the total return of the S&P 500 since 1960, making dividend investing important. Read here for a portfolio approach."}, {"date": "20240417012400", "headline": "Abbott Labs first-quarter results top estimates amid strong medical device sales", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417013300", "headline": "Abbott posts Q1 beat on MedTech even as diagnostics slump", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417013708", "headline": "Abbott: Q1 Earnings Snapshot", "summary": "ABBOTT PARK, Ill. \u2014 ABBOTT PARK, Ill. \u2014 Abbott Laboratories on Wednesday reported first-quarter profit of $1.23 billion. The Abbott Park, Illinois-based company said it had net income of..."}, {"date": "20240417015700", "headline": "Fly Intel: Pre-market Movers", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417021600", "headline": "Abbott says broad-based growth across portfolio in Q1", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417021800", "headline": "Abbott Beats Q1 Expectations With $10 Billion In Sales, $0.98 EPS", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417022500", "headline": "5 stocks to watch on Wednesday: LLY, ABT and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417022718", "headline": "Abbott: target ranges for 2024 tightened upwards", "summary": "Abbott Laboratories has tightened its target ranges for adjusted EPS and organic sales growth , to $4.55-4.70 and 8.5-10% respectively, for the current year.For the first three months of 2024, it..."}, {"date": "20240417024100", "headline": "Unusually active option classes on open April 17th", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417025900", "headline": "ABT Earnings: Abbott Beats Expectations with Q1 Earnings", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417030100", "headline": "Abbott says performance of business continues to be 'very strong'", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417030500", "headline": "Abbott Labs\u2019 first-quarter results top estimates amid strong medical-device sales", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417031100", "headline": "Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417035500", "headline": "ABT Makes Notable Cross Below Critical Moving Average", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417041500", "headline": "Abbott Labs Faces Downturn Post-Q1 Results Amid Mixed Sector Performances", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417041500", "headline": "Stock Futures Rise as More Earnings Roll In", "summary": "Futures were higher as investors moved past Fed Chair Powell\u2019s comments Tuesday that dialed back expectations for interest-rate cuts."}, {"date": "20240417044900", "headline": "Relative Strength Alert For Abbott Laboratories", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417045800", "headline": "ABT Stock Earnings: Abbott Laboratories Beats EPS, Beats Revenue for Q1 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417050000", "headline": "What You Missed On Wall Street This Morning", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417050900", "headline": "See Which Of The Latest 13F Filers Holds Abbott Laboratories", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417052700", "headline": "Wall Street Lunch: Lilly In Limelight", "summary": "Eli Lilly's tirzepatide reached main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea. Abbott posts Q1 results beat."}, {"date": "20240417053000", "headline": "Abbott beats quarterly profit estimates on strong medical device sales", "summary": "Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its forecast."}, {"date": "20240417053000", "headline": "Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges", "summary": "Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024."}, {"date": "20240417053412", "headline": "Abbott's robust medical device sales drive quarterly profit beat", "summary": "Sales of the company's medical devices have been strengthened in recent quarters due to a resurgence in the demand for joint replacements as well as other surgeries delayed during the COVID-19 pandemic.  Industry bellwether and rival Johnson & Johnson said on Tuesday it continues to expect medtech related procedure volumes to remain elevated above pre-COVID levels through 2024.  Abbott recorded medical device sales of $4.45 billion, of which its glucose monitor, FreeStyle Libre, generated $1.5 billion."}, {"date": "20240417054631", "headline": "United jumps on earnings, stocks look to snap losing streak: Yahoo Finance", "summary": "Shares of United Airlines (UAL) are higher this morning after the company's latest earnings and revenue came in better than expected. United revealed a $200 million hit to earnings due to ongoing issues with Boeing (BA) aircraft. Investors will look to United to help the overall market, which has seen a 3-day losing streak for the S&P 500 (^GSPC). Wall Street is still waiting for earnings from big names, including Netflix (NFLX), Discover (DFS), American Express (AXP), and Procter & Gamble (PG). Yahoo Finance trending tickers include AMC Entertainment (AMC), Applied Materials (AMAT), and Abbott (ABT). Key guests include:9 a.m. ET - Brian Belski, BMO Capital Markets Chief Investment Strategist9:40 a.m. ET - Nick Owens, Morningstar Industrials Equity Analyst10 a.m. ET - Jerome Schneider, PIMCO Head of Short-Term Portfolio Management11 a.m. ET - Brian Kelly, The Points Guy Founder"}, {"date": "20240417055207", "headline": "Abbott Labs Jumps, Retreats On Q1 Beat, Shy Guidance", "summary": "Abbott stock see-sawed early Wednesday after the giant health care company reported adjusted income of 98 cents a share on $10 billion in first-quarter sales. The Street projected earnings of 95 cents a share and $9.88 billion in sales, according to FactSet. During the year-earlier period, Abbott Laboratories (ABT) earned $1.03 per share and reported $9.75 billion in sales. For..."}, {"date": "20240417055828", "headline": "UPDATE 3-Abbott's robust medical device sales drive quarterly profit beat", "summary": "Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its full-year forecast on strong sales of its medical devices, including glucose-monitoring products.  Sales of the company's medical devices have been strengthened in recent quarters due to a resurgence in the demand for joint replacements as well as other surgeries delayed during the COVID-19 pandemic.  Abbott recorded medical device sales of $4.45 billion, of which its glucose monitor, FreeStyle Libre, generated $1.5 billion."}, {"date": "20240417064002", "headline": "Abbott (ABT) Tops Q1 Earnings and Revenue Estimates", "summary": "Abbott (ABT) delivered earnings and revenue surprises of 2.08% and 1.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?"}, {"date": "20240417064120", "headline": "Abbott Labs tops Q1 expectations, raises low end of 2024 guidance range", "summary": "ABBOTT PARK, Illinois \u2014 Abbott Laboratories reported a first-quarter profit of $1.23 billion Wednesday. The company, based in Abbott Park, Illinois, posted net income of 70 cents per share...."}, {"date": "20240417065118", "headline": "Abbott Laboratories (ABT) Q1 Earnings: Surpasses EPS Estimates and Raises Full-Year Guidance", "summary": "Robust Performance Driven by Medical Devices and Pharmaceuticals"}, {"date": "20240417073007", "headline": "Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say", "summary": "Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers."}, {"date": "20240417075400", "headline": "Abbott Labs Stock Is Slipping After Earnings Beat. Here\u2019s Why.", "summary": "Healthcare-products firm Abbott Laboratories\u2019 first-quarter earnings beat expectations, but second-quarter guidance was light."}, {"date": "20240417080244", "headline": "Abbott Labs posts Q1 earnings beat", "summary": "Abbott Laboratories (ABT) reported first quarter results that topped Wall Street estimates on both the top and bottom lines. The healthcare products company also raised the lower end of its full-year earnings guidance range.\u00a0 Yahoo Finance's Anjalee Khemlani breaks down the results in the video above. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Stephanie Mikulich."}, {"date": "20240417081300", "headline": "Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract", "summary": "Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024."}, {"date": "20240417084216", "headline": "Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance", "summary": "Wednesday, Abbott Laboratories (NYSE:ABT) reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Reported sales increased by 2.2%, which includes the anticipated decline in COVID-19 testing-related revenue compared to the previous year. First-quarter growth was led by Medical Devices (up 14.3% organic; 14.2% reported), with FreeStyle Libre sales growing 23.3% on an organic basis (22.4% reported) to $1."}, {"date": "20240417113012", "headline": "Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript", "summary": "ABT earnings call for the period ending March 31, 2024."}, {"date": "20240417140600", "headline": "U.S. Stocks Slide On Tech Weakness", "summary": "NEWSPLUS  1604 ET \u2013 U.S. stocks fall again as investors don\u2019t expect a rate cut from the Fed anytime soon. Technology stocks lead the losses, while more defensive sectors like utilities and consumer staples outperform."}, {"date": "20240417141107", "headline": "Abbott Undercuts Its 200-Day Line And A Flat Base Despite Its 'Solid' Quarterly Report", "summary": "Abbott Laboratories came in Wednesday with a \"solid\" first-quarter report that included a guidance raise, but Abbott stock slipped."}, {"date": "20240417224021", "headline": "Q1 2024 Abbott Laboratories Earnings Call", "summary": "Q1 2024 Abbott Laboratories Earnings Call"}, {"date": "20240417225700", "headline": "Strong Q1 Performance and Growth Prospects Justify Buy Rating for Abbott Labs", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417225800", "headline": "Buy Rating Affirmed: Abbott Labs Outperforms with Strong Q1 Sales and Upward Earnings Revision", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417230100", "headline": "Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), US Physical Therapy (USPH)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417233500", "headline": "5 Dividend Aristocrats Where Analysts See Capital Gains", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418004100", "headline": "3 Best Stocks to Buy Now, 4/18/2024, According to Top Analysts", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418010113", "headline": "Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations ...", "summary": "Abbott Laboratories reports robust Q1 performance with significant sales growth and upward revisions in annual forecasts."}, {"date": "20240418020100", "headline": "Abbott price target lowered by $3 at Raymond James, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418021500", "headline": "Abbott price target lowered by $3 at RBC Capital, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418023100", "headline": "Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Elevance Health (ELV)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418024500", "headline": "Abbott Q1 strong but still in penalty box on litigation overhang, says Bernstein", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418050159", "headline": "Abbott Laboratories First Quarter 2024 Earnings: EPS Beats Expectations", "summary": "Abbott Laboratories ( NYSE:ABT ) First Quarter 2024 Results Key Financial Results Revenue: US$9.96b (up 2.2% from 1Q..."}, {"date": "20240418063800", "headline": "Behind the Scenes of Abbott Laboratories's Latest Options Trends", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418064112", "headline": "Abbott Laboratories (NYSE:ABT) Q1 2024 Earnings Call Transcript", "summary": "Abbott Laboratories (NYSE:ABT) Q1 2024 Earnings Call Transcript April 17, 2024 Abbott Laboratories isn\u2019t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Robert Ford \u2013 Chairman and Chief Executive Officer: Phil Boudreau \u2013 Senior Vice President, Finance and Chief Financial Officer: Bob [\u2026]"}, {"date": "20240418202500", "headline": "At least 70% of the S&P 500 names that reported results this week topped estimates - Earnings Scorecard", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419050758", "headline": "Results: Abbott Laboratories Beat Earnings Expectations And Analysts Now Have New Forecasts", "summary": "Abbott Laboratories ( NYSE:ABT ) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to..."}, {"date": "20240419074459", "headline": "Should You Expect Accelerating Earnings Growth for Abbott Laboratories (ABT)?", "summary": "Polen Capital, an investment management company, released its \u201cPolen Focus Growth Strategy\u201d first quarter 2024 investor letter. A copy of the same can be downloaded here. The US stock market started 2024 optimistically. In the first quarter, the fund returned 8.29% (gross) and 8.09% (net) compared to 11.41% for the Russell 1000 Growth Index and [\u2026]"}, {"date": "20240420010000", "headline": "20 Years To $300k? Building A $10,000 Dividend Portfolio From Scratch", "summary": "Focusing on consistent dividend growth can lead to higher returns in lower-risk areas. Read an analysis of the portfolio here."}, {"date": "20240420020310", "headline": "IGA: This 12% Yielding Global Equity CEF Now Pays Monthly", "summary": "Read about the recent market correction as S&P 500 falls below 5000, Voya funds' distribution changes, and the attractive 12% annual yield of IGA fund. Explore more here."}, {"date": "20240420060300", "headline": "THQ: Collecting A High Yield From Increased Medical Spending", "summary": "abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield and exposure to diverse healthcare subsectors, outperforming peers. Explore more here."}, {"date": "20240420064439", "headline": "We Think Some Shareholders May Hesitate To Increase Abbott Laboratories' (NYSE:ABT) CEO Compensation", "summary": "Key Insights Abbott Laboratories to hold its Annual General Meeting on 26th of April Total pay for CEO Robert Ford..."}, {"date": "20240421195100", "headline": "Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421205100", "headline": "Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Eli Lilly & Co (LLY)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421225000", "headline": "Abbott price target lowered by $1 at Barclays, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422010400", "headline": "3 Dividend Kings Down 11% You\u2019ll Regret Not Buying on the Dip", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422061900", "headline": "Why I Believe Abbott Is Much Better Positioned In Today's Rising Inflation Scenario", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422070011", "headline": "Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know", "summary": "Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock."}, {"date": "20240422220500", "headline": "3 Best Stocks to Buy Now, 4/23/2024, According to Top Analysts", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423010020", "headline": "Not A Millionaire? No Problem! Here's A 10-Stock Portfolio To Retire Comfortably", "summary": "Most retirees are managing to thrive in retirement with less savings than expected. Check here to learn more about a 10-stock portfolio to retire comfortably."}, {"date": "20240423020400", "headline": "It's Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423134500", "headline": "It\u2019s Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team", "summary": "NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ..."}, {"date": "20240423144125", "headline": "Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes", "summary": "Because dividend investing has such an impressive track record of beating non-dividend-paying stocks, many investors buy Dividend Aristocrats for their portfolios. It\u2019s not a bad strategy to begin with. Dividend Aristocrats are stocks on the S&P 500 that have consistently raised their payouts for 25 years or more. Studies show stocks that initiate a dividend and then raise them over time have outperformed all other stocks over time. Yet, there are limits to the strategy. As Walgreens Boots Allia"}, {"date": "20240424214000", "headline": "Abbott Laboratories stock outperforms competitors despite losses on the day", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424224500", "headline": "Intelligent Bio Solutions\u2019 Fingerprint Drug Screening Technology Poised For Massive Growth", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425222800", "headline": "3 Best Healthcare Stocks to Buy in April 2024, According to Analysts", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426042200", "headline": "ABT July 19th Options Begin Trading", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426130922", "headline": "ABT, DHR, DXCM: Which \u201cStrong Buy\u201d Healthcare Stock Has More Upside?", "summary": "The healthcare scene is home to some pretty defensive companies that aren\u2019t exactly shying away from medical innovation. With the following Strong-Buy-rated health stocks (ABT, DHR, and DXCM), investors may just be able to get growth, relative defensiveness, and decent multiples as we head into May 2024. Undoubtedly, investors may wish to come for the underestimated growth and stay for their ability to move higher, even as the market tides turn against most stocks in the market. Therefore, in th"}, {"date": "20240428054500", "headline": "2 Beaten-Down Dividend Stocks to Buy and Hold Forever", "summary": "These companies aren't in danger of becoming has-beens."}, {"date": "20240429020400", "headline": "Abbott's dissolving stent receives FDA approval for arteries below the knee", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429023000", "headline": "DexCom, Insulet, Tandem seen benefitting the most in diabetes survey - Wells Fargo", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429025900", "headline": "Abbott gets FDA approval for Esprit BTK stent for PAD", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429070000", "headline": "Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee", "summary": "Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit\u2122 BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving."}, {"date": "20240429230400", "headline": "7 Defensive Stocks Built to Withstand the Market\u2019s Worst Storms", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429232100", "headline": "Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), Iterum Therapeutics (ITRM)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430094015", "headline": "PBH vs. ABT: Which Stock Is the Better Value Option?", "summary": "PBH vs. ABT: Which Stock Is the Better Value Option?"}, {"date": "20240430210200", "headline": "Stock Market Crash Alert: 3 Must-Buy Healthcare Stocks When Prices Plunge", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430211400", "headline": "Abbott Labs EVP of Finance Robert Funck Retires After 36 Years", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430215200", "headline": "What the Options Market Tells Us About Abbott Laboratories", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501000100", "headline": "Invest with Confidence: Intrinsic Value Unveiled of Abbott Laboratories", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501070018", "headline": "Is Trending Stock Abbott Laboratories (ABT) a Buy Now?", "summary": "Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store."}, {"date": "20240503021900", "headline": "How Is The Market Feeling About Abbott Laboratories?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503043000", "headline": "June 14th Options Now Available For Abbott Laboratories (ABT)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}]}